Warner-Lambert/Parke-Davis Professor of Medicine
Professor of Internal Medicine
Professor of Pharmacology
Professor of Medicinal Chemistry
College of Pharmacy
[email protected]
Available to mentor
Shaomeng Wang, PhD
Professor
-
Center MemberCenter for Computational Medicine and Bioinformatics
-
Center MemberRogel Cancer Center
-
Wei X, Lu Y, Lin LL, Zhang C, Chen X, Wang S, Wu SA, Li ZJ, Quan Y, Sun S, Qi L. Nat Commun, 2024 Jan 22; 15 (1): 659Journal ArticleProteomic screens of SEL1L-HRD1 ER-associated degradation substrates reveal its role in glycosylphosphatidylinositol-anchored protein biogenesis.
DOI:10.1038/s41467-024-44948-2 PMID: 38253565 -
Rej RK, Hu B, Chen Z, Acharyya RK, Wu D, Metwally H, McEachern D, Wang Y, Jiang W, Bai L, Nishimura LS, Gersch CL, Wang M, Wen B, Sun D, Carlson K, Katzenellenbogen JA, Xu G, Zhang W, Wu W, Priestley ES, Sui Z, Rae JM, Wang S. J Med Chem, 2024 Nov 25;Journal ArticleDiscovery of ERD-12310A as an Exceptionally Potent and Orally Efficacious PROTAC Degrader of Estrogen Receptor α (ERα).
DOI:10.1021/acs.jmedchem.4c01401 PMID: 39585895 -
Li Z, Harikrishnan LS, Xu G, Samanta D, Clemente JC, Leng L, Tu W, Yang L, Huang L, Wang M, Wang S, Deng Q, Behshad E, Nagilla R, Orth P, Rice C, Strickland C, Mohammad HP, Priestley ES, Sui Z. J Med Chem, 2024 Nov 21;Journal ArticleDiscovery of Potent, Highly Selective, and Efficacious SMARCA2 Degraders.
DOI:10.1021/acs.jmedchem.4c01878 PMID: 39570797 -
Acharyya RK, Rej RK, Hu B, Chen Z, Wu D, Lu J, Metwally H, McEachern D, Wang Y, Jiang W, Bai L, Tošović J, Gersch CL, Xu G, Zhang W, Wu W, Priestley ES, Sui Z, Sarkari F, Wen B, Sun D, Rae JM, Wang S. J Med Chem, 2024 Nov 14; 67 (21): 19010 - 19037.Journal ArticleDiscovery of ERD-1233 as a Potent and Orally Efficacious Estrogen Receptor PROTAC Degrader for the Treatment of ER+ Human Breast Cancer.
DOI:10.1021/acs.jmedchem.4c01521 PMID: 39485242 -
Aguilar A, Yang J, Li Y, McEachern D, Huang L, Razzouk S, Wang S. J Med Chem, 2024 Nov 14; 67 (21): 19503 - 19518.Journal ArticleDiscovery of MD-265: A Potent MDM2 Degrader That Achieves Complete Tumor Regression and Improves Long-Term Survival of Mice with Leukemia.
DOI:10.1021/acs.jmedchem.4c01818 PMID: 39480241 -
Kregel S, Wang C, Han X, Xiao L, Fernandez-Salas E, Bawa P, McCollum BL, Wilder-Romans K, Apel IJ, Cao X, Speers C, Wang S, Chinnaiyan AM. Neoplasia, 2024 Nov; 57: 101064Journal ArticleCorrigendum to "Androgen receptor degraders overcome common resistance mechanisms developed during prostate cancer treatment" [Neoplasia, Volume 22, Issue 2 (2020) 111-119].
DOI:10.1016/j.neo.2024.101064 PMID: 39389678 -
Sun J, Corradini S, Azab F, Shokeen M, Muz B, Miari KE, Maksimos M, Diedrich C, Asare O, Alhallak K, Park C, Lubben B, Chen Y, Adebayo O, Bash H, Kelley S, Fiala M, Bender DE, Zhou H, Wang S, Vij R, Williams MTS, Azab AK. Leukemia, 2024 Nov; 38 (11): 2355 - 2365.Journal ArticleIL-10R inhibition reprograms tumor-associated macrophages and reverses drug resistance in multiple myeloma.
DOI:10.1038/s41375-024-02391-8 PMID: 39215060 -
Sun D, Macedonia C, Chen Z, Chandrasekaran S, Najarian K, Zhou S, Cernak T, Ellingrod VL, Jagadish HV, Marini B, Pai M, Violi A, Rech JC, Wang S, Li Y, Athey B, Omenn GS. J Med Chem, 2024 Sep 26; 67 (18): 16035 - 16055.Journal ArticleCan Machine Learning Overcome the 95% Failure Rate and Reality that Only 30% of Approved Cancer Drugs Meaningfully Extend Patient Survival?
DOI:10.1021/acs.jmedchem.4c01684 PMID: 39253942
